Kevin Kunzmann

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.

A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.

A new contribution of data evidences the "controversial" use of concomitant steroids in patients who do not benefit from monotherapy anti-VEGF.

A new study shows BCVA scores and blood levels of AA/EPA significantly improved in treated patients with dry AMD or Stargardt disease at 24 weeks.

An investigation into the diffusion, capacity and drug concentrations showed predictable flexibility with the novel ophthalmic implant device.

Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.

Stephanie Lovinsky-Desir, MD, MS, discusses key findings from the 2022 ALA State of the Air Report.

Erica Marsh, MD, MSCI, discusses the role of new drug classes like GnRH antagonists, as well as the adoption of remote screening options following COVID-19 response.

Erica Marsh, MD, MSCI, discusses the need for improved patient involvement and open discussion in the highly prevalent, potentially psychologically impactful condition.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

The company reported interim results at a meeting this week showing multiple formulations were tolerable and safe. Next comes a phase 2 trial.

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

Bianca K. Frogner, PhD, discusses the prevalence of burnout and job dissatisfaction observed across various health care worker roles and settings.

The investigative gene therapy achieved significant phase 3 endpoints, after receiving feedback from the FDA on its efficacy outcomes in 2020.

A systematic literature review highlighted key risk factors that could constitute a risk assessment model for hemophilia bleeding—a currently lacking guidance for clinicians.

Data show the life expectancy of Hispanic and non-Hispanic Black Americans decreased by more than 3 years during the pandemic.

The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.

A study highlights methods to define hydroxyurea exposure as means of understanding hematologic benefit derived from the first-line drug for children.

A survey analysis suggests the worst of turnover in the workforce occurred in 2020, but focus is needed to recover health care workers from specific fields.

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

National registry data suggest management and outcomes of ST-elevation myocardial infarction are returning to pre-pandemic levels, though vaccinated patients have fared better in mortality.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.